← All trials
NCT00538382
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2007
- Primary completion
- Nov 1, 2008
- Completion date
- Dec 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 51
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- National Institute of Dental and Craniofacial Research (NIDCR)Collaborator
- National Cancer Institute (NCI)Collaborator
- RTI InternationalCollaborator
- University of North Carolina at Chapel HillCollaborator
- Bill and Melinda Gates FoundationCollaborator
- National Institutes of Health (NIH)Collaborator
- University of KinshasaOverall official - principal investigator
- University of KinshasaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.